Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | FASN | P49327 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18092641 | 0.89 | MAPT (0.69) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL602647 | 0.88 | MAPT (0.67) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL18092595 | 0.85 | MAPT (0.63) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL18092665 | 0.83 | MAPT (0.61) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL3950606 | 0.83 | HSD17B10 (0.49) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4930087 | 0.81 | KMT2A (0.63) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL3944802 | 0.81 | MAPT (1.00) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL18092646 | 0.80 | MAPT (0.56) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL18102160 | 0.79 | MAPT (0.81) | MAPTKMT2AMEN1KDM4EFASN | |
| SCHEMBL18092674 | 0.79 | MAPT (0.81) | MAPTKMT2AMEN1KDM4EFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| EP-1802572-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
| WO-2006032541-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY2, ADCY5 | MAPT 4671/4885KMT2A 4518/4885MEN1 712/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | MAPT 4671/4885KMT2A 4518/4885MEN1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.